eLAS® Suite

Facilitating SLE Clinical Trials

Systemic Lupus Erythematosus (SLE) clinical trials are complex. 

The use of multiple questionnaires, each with different scoring systems, can complicate and confuse data collection and analysis.

Clinical ink has developed a fit-for-purpose Electronic Lupus Assessment Suite (eLAS®) of tools that facilitate data collection and patient engagement and ensure SLE research is straightforward, efficient, and reliable.

Lupus Clinical Trials at Clinical ink

Solving the Complexity of SLE Trials

Information gathering to understand human immunology and, particularly, how lupus affects each individual patient is critical. However, Lupus research today uses multiple questionnaires, often duplicative using different symptom-scoring criteria. Those hinder patient participation, data quality, and clinical trial outcomes.

Using eSource technology, Clinical ink solves the complexity of SLE trials by deploying Direct Data Capture (DDC) technology. DDC enables information sharing between forms, and displays prompts that clarify the proper evaluation methods for each particular questionnaire.

Leveraging DDC, the Clinical ink Electronic Lupus Assessment Suite (eLAS®) has set the standard for data collection in Lupus research by integrating the most-often used diagnostic questionnaires (BILAG, SLEDAI, CLASI). Designed to be applied during the patient visit, eLAS® delivers an intuitive interface and the ability to display data from previous visits. When the visit is complete, so is the documentation.

Why eLAS®?

Designed to be applied during the patient visit, eLAS® delivers an intuitive interface and the ability to display data from previous visits. When the visit is complete, so is the documentation.

  • Easily capture data, online or offline
  • Connect data that matters, including unstructured supporting data
  • Validate data at the time of capture
  • Pre-program workflows and study processes to ease site burden
  • Reduce workload and improve data quality
  • Share data and reports immediately, across the study team
  • Optimize decision making
Immunology clinical trial data analysis

eLAS® engages patients through straightforward, efficient, and reliable direct data capture enabling data corrections during patient visits.

Frequently Asked Questions

SLE trials are inherently complex due to several factors:


  • Diverse Symptomatology: Lupus affects individuals differently, presenting a wide range of symptoms that can vary in severity.
  • Multiple Questionnaires: Research often relies on several different questionnaires, each with unique scoring systems. These varying criteria can lead to confusion and inconsistency in data collection.
  • Challenging Data Analysis: The combination of diverse symptoms and multiple assessment tools can complicate data analysis, hindering the understanding of how lupus affects each patient.
  • Patient Participation: The complexity of symptom-scoring and the use of multiple questionnaires can deter patient participation, impacting both data quality and clinical trial outcomes.

The multifaceted nature of the disease, coupled with the challenges in data collection and analysis, contributes to the complexity of SLE trials. Solutions like Clinical ink eLAS® are developed to address these challenges by streamlining data collection and enhancing patient engagement, making SLE research more efficient and reliable.

SLE assessments are designed to evaluate the diverse symptoms and impacts of lupus on individuals. Common assessments used in SLE research include:


  • BILAG (British Isles Lupus Assessment Group): An index used to assess disease activity, focusing on different organ systems.
  • SLEDAI (Systemic Lupus Erythematosus Disease Activity Index): Measures disease activity in SLE by evaluating a combination of symptoms and laboratory results.
  • CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): Specifically targets the assessment of skin-related symptoms in lupus patients.
  • SLICC/ACR (Systemic Lupus International Collaborating Clinics/American College of Rheumatology): A damage index that evaluates the accumulated damage in various organ systems, not attributed to active lupus inflammation.
  • Patient-Reported Outcomes(PROs): These are self-reported questionnaires that capture the patient's perspective on their symptoms, functional status, and well-being.

The complexity of SLE often necessitates the use of several of these assessments in conjunction to provide a comprehensive view of the disease's activity, severity, and impact on the patient. Solutions like Clinical ink eLAS® help in integrating these assessments and streamlining the process, enhancing the efficiency, and reliability of SLE trials.

Researchers conduct lupus clinical trials to test new treatments, therapies, and interventions in order to advance medical knowledge about this complex autoimmune disease. They aim to find more effective, safer, and innovative ways to manage lupus symptoms, reduce disease flares, improve patients' quality of life, and ultimately discover a lupus cure.
Lupus clinical trials are research studies conducted with lupus patients to test new medications, treatments, or therapeutic approaches. These trials follow strict scientific guidelines and protocols. Participants are carefully monitored, and their health data is collected and analyzed.
Scroll to Top